These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 2086386)

  • 1. Iron metabolism in thalassemia intermedia.
    Fiorelli G; Fargion S; Piperno A; Battafarano N; Cappellini MD
    Haematologica; 1990; 75 Suppl 5():89-95. PubMed ID: 2086386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron overload in thalassemia: comparative analysis of magnetic resonance imaging, serum ferritin and iron content of the liver.
    Mazza P; Giua R; De Marco S; Bonetti MG; Amurri B; Masi C; Lazzari G; Rizzo C; Cervellera M; Peluso A
    Haematologica; 1995; 80(5):398-404. PubMed ID: 8566878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron metabolism and iron chelation in the thalassaemia disorders.
    Pippard MJ
    Haematologica; 1990; 75 Suppl 5():66-71. PubMed ID: 2086383
    [No Abstract]   [Full Text] [Related]  

  • 4. Liver iron concentrations and urinary hepcidin in beta-thalassemia.
    Origa R; Galanello R; Ganz T; Giagu N; Maccioni L; Faa G; Nemeth E
    Haematologica; 2007 May; 92(5):583-8. PubMed ID: 17488680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chelating therapy in beta-thalassemia].
    Musumeci S; Romeo MA; Di Gregorio F; Schiliró G; Russo G
    Pediatr Med Chir; 1982; 4(1-2):55-9. PubMed ID: 7111040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Nuclear magnetic resonance and iron overload in thalassemia].
    Schettini F; De Mattia D; Cavallo L; Sabato V; Santoro N; Del Vecchio GC; Martinelli G; Martinelli A; Di Bartolomeo P; Di Girolamo G
    Minerva Pediatr; 1991 Dec; 43(12):777-81. PubMed ID: 1798402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The treatment of Cooley's anemia.
    Nathan DG
    Haematologica; 1990; 75 Suppl 5():57-65. PubMed ID: 2086382
    [No Abstract]   [Full Text] [Related]  

  • 8. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
    Giardina PJ; Grady RW
    Semin Hematol; 1995 Oct; 32(4):304-12. PubMed ID: 8560288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron chelating therapy in thalassemia: current problems.
    Russo G
    Haematologica; 1990; 75 Suppl 5():84-8. PubMed ID: 2086385
    [No Abstract]   [Full Text] [Related]  

  • 10. The correlation of transferrin saturation and ferritin in non-splenectomized thalassemic children.
    Wangruangsathit S; Hathirat P; Chuansumrit A; Pakakasama S; Hongeng S
    J Med Assoc Thai; 1999 Nov; 82 Suppl 1():S74-6. PubMed ID: 10730522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron chelation in thalassemia: mechanism of desferrioxamine action.
    Hershko C; Rachmilewitz EA
    Isr J Med Sci; 1978 Nov; 14(11):1111-5. PubMed ID: 750535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-transferrin-bound iron during blood transfusion cycles in beta-thalassemia major.
    Grosse R; Lund U; Caruso V; Fischer R; Janka GE; Magnano C; Engelhardt R; Dürken M; Nielsen P
    Ann N Y Acad Sci; 2005; 1054():429-32. PubMed ID: 16339692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High nontransferrin bound iron levels and heart disease in thalassemia major.
    Piga A; Longo F; Duca L; Roggero S; Vinciguerra T; Calabrese R; Hershko C; Cappellini MD
    Am J Hematol; 2009 Jan; 84(1):29-33. PubMed ID: 19006228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levels of non-transferrin-bound iron as an index of iron overload in patients with thalassaemia intermedia.
    Taher A; Musallam KM; El Rassi F; Duca L; Inati A; Koussa S; Cappellini MD
    Br J Haematol; 2009 Sep; 146(5):569-72. PubMed ID: 19604239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical studies on iron chelation in patients with thalassemia major.
    Freedman MH; Olivieri N; Benson L; Liu P; McClelland R; St Louis P; Templeton D; Koren G
    Haematologica; 1990; 75 Suppl 5():74-83. PubMed ID: 2086384
    [No Abstract]   [Full Text] [Related]  

  • 16. [Iron overload in a beta thalassemia heterozygote of the intermediate type in a subject of Alsation origin. Results of iron chelation treatment].
    North ML; Lang JM; Bergerat JP; Giron C; Oberling F; Mayer S
    Nouv Rev Fr Hematol (1978); 1984; 26(5):317-21. PubMed ID: 6334273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone marrow transplantation in adults with thalassemia: Treatment and long-term follow-up.
    Gaziev J; Sodani P; Polchi P; Andreani M; Lucarelli G
    Ann N Y Acad Sci; 2005; 1054():196-205. PubMed ID: 16339666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of iron balance in homozygous beta-thalassemia subjects treated with desferrioxamine administered subcutaneously].
    Ferrara M; Galdo Capotorti M; Ponte G; Esposito L
    Pediatria (Napoli); 1983; 91(4):371-7. PubMed ID: 6545400
    [No Abstract]   [Full Text] [Related]  

  • 19. Retrospective clinical remarks in thalassemia intermedia.
    Dore F; Cianciulli P; Oggiano L; Pardini S; Bonfigli S; Ganau A; Piga G; Trua G; Papa G; Longinotti M
    Haematologica; 1990; 75 Suppl 5():9-25. PubMed ID: 2086387
    [No Abstract]   [Full Text] [Related]  

  • 20. Desferrioxamine induced urinary iron excretion in thalassemia.
    Dubey AP; Kumar S; Choudhury P; Talukdar B; Puri RK
    Indian Pediatr; 1993 Jun; 30(6):775-8. PubMed ID: 8132258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.